Note 2023 $’000 2022 $’000 Revenue from contracts with customers 4 231,925 14,553 Other income 4 8,138 2,480 Total income 240,063 17,033 Research and development costs (26,751) (12,712) Corporate and administrative costs (5,946) (3,437) Loss on financial derivatives measured at fair value through profit or loss (2,226) (700) Profit before income tax 205,140 184 Income tax 6 (48,059) – Profit after income tax 157,081 184 Other comprehensive income, net of tax Amounts which may be subsequently reclassified to profit or loss: Exchange differences on translation of foreign operations (10) 2 Total comprehensive income for the year 157,071 186 Profit after tax attributable to Equity holders of the Company: 157,081 184 Total comprehensive income attributable to Equity holders of the Company: 157,071 186 Basic earnings per share 7 $1.236 $0.001 Diluted earnings per share 7 $1.201 $0.001 The notes on pages 34 to 50 form part of these consolidated financial statements. CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME FOR THE YEAR ENDED 31 DECEMBER 2023 Neuren Pharmaceuticals Limited Annual Report 2023 30
RkJQdWJsaXNoZXIy MjE2NDg3